I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast Neoplasms Breast Cancer Breast Tumors Angiosarcoma I-SPY 2 Neoadjuvant Breast Cancer Neoplasm Adaptive pCR Pathologic Complete Response Biomarkers signature MRI Volume Hemangiosarcoma Metformin Paclitaxel Ado-trastuzumab emtansine Doxorubicin Irinotecan Pembrolizumab Trastuzumab Durvalumab Olaparib Pertuzumab Veliparib Talazoparib Trebananib Cemiplimab AMG 386 with or without Trastuzumab AMG 479 (Ganitumab) plus Metformin MK-2206 with or without Trastuzumab AMG 386 and Trastuzumab T-DM1 and Pertuzumab Pertuzumab and Trastuzumab Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab - 4 cycle Talazoparib plus Irinotecan Patritumab and Trastuzumab Pembrolizumab - 8 cycle SGN-LIV1A Durvalumab plus Olaparib SD-101 + Pembrolizumab Tucatinib Cemiplimab plus REGN3767 AMG 479 plus Metformin Pembrolizumab 4 cycle Pembrolizumab 8 cycle
Lead Scientist at UCSD
- Anne Wallace, MD
Dr. Wallace employs nuclear and fluorescence imaging to detect and stage melanoma and breast cancer. She also employs advanced imaging techniques to study stem cell reconstructive surgery. Dr. Anne Wallace is a member of both the Division of General Surgery and the Division of Plastic Surgery. She has directed the breast program since 1995 at the UC San Diego Moores Cancer Center.